A multicenter trial evaluated the Hsp90 inhibitor, retaspimycin HCL (IPI-504), plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer, although only modest clinical activity was observed that did not meet criteria for trial expansion [216]. This evidence concerns the gene ERBB2 and breast carcinoma.